The ministry of Health in Uganda has launched an extensive newborn screening initiative designed to tackle sickle cell disease (SCD), a major public health issue in the nation.
This program is vital as it focuses on the early identification and management of sickle cell disease, which can result in serious health complications if not addressed promptly. Sickle cell disease is a hereditary blood disorder marked by the production of abnormal hemoglobin, referred to as hemoglobin S.
This defect causes red blood cells to take on a stiff, sickle-like form, leading to a range of health challenges, including painful crises, a heightened risk of infections, and potential organ damage.
Sickle cell disease affects approximately one per cent of the Ugandan population, and estimated 312,302 births annually worldwide. The Uganda Sickle Surveillance Study (US3) revealed a sickle cell trait prevalence of 13.3 per cent and a sickle cell disease prevalence of 1.3 per cent, indicating a significant public health challenge.
Without early detection and intervention, many affected infants face life-threatening complications Prof Grace Ndeezi’s research reveals concerning statistics about the prevalence of sickle cell disease (SCD) in Uganda:
• Western Region: Roughly 4.1 per cent.
• Central Region: The prevalence is around 10 per cent.
• Eastern Region: Approximately 17 per cent.
• Northern Region: This area shows a significantly higher prevalence at about 18 per cent with Alebtong district having the highest prevalence at 23.8 per cent.
These figures highlight the critical need for effective screening and management approaches throughout the country. In response to the increasing challenge posed by sickle cell disease, the ministry of Health has established outstanding regional centers of excellence in all regional referral hospitals.
These centers are staffed with specialized professionals and equipped with the necessary resources to deliver comprehensive care for individuals with sickle cell disease. They are essential in promoting early diagnosis through newborn screening initiatives and ensuring that those affected receive the appropriate treatment and support.
Operated by the Uganda National Health Laboratory Services in Luzira, these centers function under the national sickle cell program. Newborn screening for sickle cell disease allows for early diagnosis before symptoms manifest.
This is crucial because infants with SCD are asymptomatic during their first six months due to the presence of fetal hemoglobin (HbF), which protects them from the effects of sickle hemoglobin (HbS).
Early diagnosis enables timely interventions such as penicillin prophylaxis and vaccinations against pneumococcal infections, which are vital in reducing morbidity and mortality associated with sickle cell disease.
A significant advancement in newborn screening is represented by the newly launched Kayunga Sickle Cell project, a collaboration between Baylor Uganda, Texas Children’s hospital in the USA, and the Sickle Pan-Africa Research Consortium (SPARCo) at Lira and Mbale regional referral hospitals.
This initiative aims to bolster the newborn screening efforts already initiated by the ministry of Health. It emphasizes the education of healthcare providers and communities regarding sickle cell disease while enhancing access to testing services and improving the care and management of sickle cell patients.
The project plays a crucial role in facilitating early diagnosis through newborn screening programs, ensuring that affected individuals receive the necessary care and support, along with consistent follow-up.
In spite of remarkable progress, notable gaps persist in enhancing awareness and advocacy for sickle cell disease testing within communities. Access to affordable medication continues to pose a significant challenge nationwide.
A considerable number of individuals remain uninformed about the condition, resulting in a low uptake of screening services. To combat these issues, organizations such as Catherine Phil Sickle Cell Support Initiative, Rare Mark Foundation, Sickle Cell Association of Uganda, Uganda Sickle Cell Rescue Foundation, Tackle Sickle Cell Africa, Raising Hope International Friends, Manzi Sickle Cell Foundation, Pen-Plus Uganda, and Nicosam Healthcare Uganda have joined forces.
They are actively conducting community outreach programs designed to elevate awareness, promote testing, advocate for the economic empowerment of affected families, and support research initiatives.
Various community stakeholders, including churches, media outlets, politicians, and traditional leaders, have also participated in these awareness campaigns. In the previous year, Catherine Phil Sickle Cell Support Initiative orchestrated a fundraising run in Lira City aimed at acquiring hemoglobin electrophoresis machines for both Lira regional referral hospital and Alebtong health centre IV, which have since been successfully delivered.
This initiative not only generated vital funds but also functioned as a significant awareness campaign, emphasizing the critical need for early detection and effective management of sickle cell disease.
The event was graced by the presence of the minister of Health, Dr Jane Ruth Aceng Ocero, alongside the Lira city Woman MP, who represented the First Lady, Mama Janet Kataaha Museveni, as the chief guest.
With the ongoing commitment from various stakeholders, including regional centers of excellence and community organizations, there is a promising outlook for enhanced awareness, advocacy, and improved access to medication for those affected by this condition.
Nevertheless, sustained advocacy and education remain crucial to ensure that all Ugandans recognize the importance of early detection through newborn screening. Uganda has the opportunity to markedly decrease both morbidity and mortality rates in infants affected by sickle cell disease, ultimately fostering improved health outcomes for the population.
ed@capsci-uganda.org
The writer is the executive director of Catherine Sickle Cell Support Initiative
We shall stand by everyone who comes on board with the intention of combating the deadly sicklecell disease.